Moderna's mFLUSIVA approval offers a regulatory case study for mRNA vaccine sponsors, covering comparator selection lessons from the FDA's reversed refusal-to-file, competitive implications for Pfizer and Sanofi's mRNA flu programs, and what the accelerated approval pathway means for long-term regulatory risk.
Moderna's mFLUSIVA approval on August 5, 2026, marks a milestone for mRNA vaccine development, offering insight into regulatory considerations that may influence future mRNA vaccine submissions, including comparator selection, accelerated approval strategies, and clinical development planning.
